Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Early identification of neuromyelitis optica allows aggressive acute and prophylactic relapse management aimed at preventing disability. Since the discovery of pathogenic aquaporin-4 antibodies the neuromyelitis optica spectrum has widened significantly: brain lesions no longer preclude the diagnosis and there are reports of symptoms of cerebral origin presenting as the first manifestation of the condition, prior to optic nerve or spinal cord disease. Defining antibody negative neuromyelitis optica, and distinguishing it from other inflammatory disorders such as multiple sclerosis can therefore be a challenge. In this review we discuss the role of conventional imaging in the diagnosis of neuromyelitis optica, and the scope of quantitative MRI modalities to identify more specific pathophysiological features to aid in the differentiation from other conditions and assess treatment response. © 2013 Elsevier B.V. All rights reserved.

Original publication




Journal article


Multiple Sclerosis and Related Disorders

Publication Date





284 - 293